Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Arcturus Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of RNA-based medicines. The company operates primarily in the biotechnology and pharmaceutical research and development industries, with a core emphasis on messenger RNA (mRNA) therapeutics and vaccines. Its business model centers on leveraging proprietary RNA drug delivery and manufacturing technologies to address infectious diseases and rare genetic disorders with high unmet medical need.
The company’s primary revenue drivers to date have been collaboration payments, grants, and licensing revenue rather than product sales, reflecting its clinical-stage status. Arcturus is best known for its LUNAR® lipid-mediated delivery platform, which is designed to enable targeted and durable RNA expression at lower doses. Founded in 2013, the company evolved from early RNA chemistry and delivery research into a diversified pipeline of mRNA vaccines and therapeutics, culminating in public listing on Nasdaq in 2018 and subsequent late-stage clinical development partnerships.
Business Operations
Arcturus conducts its operations through integrated research, development, and early manufacturing activities, with its pipeline organized around mRNA vaccines and mRNA therapeutic candidates. The company generates revenue through strategic collaborations, upfront and milestone payments, and research funding, while internally advancing wholly owned programs. Its lead assets include ARCT-154, a next-generation COVID-19 mRNA vaccine candidate, and ARCT-810, an mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency.
Operations span both domestic and international activities, including clinical trials conducted in multiple countries. Arcturus controls proprietary technologies such as LUNAR®, STARR® mRNA, and in-house mRNA manufacturing processes. A major partnership includes its global collaboration with CSL Seqirus for the development and commercialization of ARCT-154, under which CSL is responsible for late-stage development, manufacturing scale-up, and commercialization in most global markets.
Strategic Position & Investments
Strategically, Arcturus positions itself as a differentiated mRNA company focused on lower-dose, longer-duration RNA expression compared to first-generation mRNA platforms. Growth initiatives prioritize advancing late-stage clinical programs, expanding indications for its delivery platform, and selectively entering partnerships that offset development risk while preserving long-term value. The company continues to invest heavily in clinical trials, process development, and intellectual property protection.
Key investments include continued development of rare disease therapeutics and next-generation vaccines, as well as manufacturing capabilities to support clinical and potential commercial supply. Notable assets include wholly owned pipeline candidates and the collaboration-linked program with CSL Seqirus, which represents a significant strategic and financial investment. Emerging areas of focus include self-amplifying mRNA technologies and improved lipid nanoparticle formulations to broaden therapeutic applicability.
Geographic Footprint
Arcturus is headquartered in the United States, with its principal executive offices in California. The company maintains a global operational footprint through international clinical trials, research collaborations, and commercialization partnerships, particularly in North America, Europe, and parts of Asia-Pacific.
Its partnership with CSL Seqirus significantly extends Arcturus’s international reach, providing access to established commercial infrastructure across Europe, Australia, and other global vaccine markets. While Arcturus itself maintains a relatively lean physical presence outside the U.S., its international influence is driven by outsourced clinical operations and strategic alliances rather than large foreign subsidiaries.
Leadership & Governance
Arcturus was co-founded by scientific and industry leaders with expertise in RNA biology and drug development, and it is led by an executive team emphasizing innovation, capital discipline, and platform scalability. The leadership’s strategic vision focuses on translating proprietary RNA technologies into clinically meaningful and commercially viable medicines through a combination of internal development and external partnerships.
Key executives include:
- Joseph E. Payne – President & Chief Executive Officer
- Juan de la Torre – Chief Operating Officer
- Padmanabh (Pad) Chivukula – Chief Scientific Officer
- Sandi Baccus – Chief Financial Officer
- Bonnie J. Anderson – Chair of the Board
The company is governed by an independent board with experience across biotechnology, pharmaceuticals, and public company oversight, aligning governance practices with U.S. public market and regulatory standards.